SMARCB1/INI1 germline mutations contribute to 10% of sporadic schwannomatosis. - Inserm - Institut national de la santé et de la recherche médicale Access content directly
Journal Articles BMC Neurology Year : 2011

SMARCB1/INI1 germline mutations contribute to 10% of sporadic schwannomatosis.

Abstract

BACKGROUND: Schwannomatosis is a disease characterized by multiple non-vestibular schwannomas. Although biallelic NF2 mutations are found in schwannomas, no germ line event is detected in schwannomatosis patients. In contrast, germline mutations of the SMARCB1 (INI1) tumor suppressor gene were described in familial and sporadic schwannomatosis patients. METHODS: To delineate the SMARCB1 gene contribution, the nine coding exons were sequenced in a series of 56 patients affected with a variable number of non-vestibular schwannomas. RESULTS: Nine variants scattered along the sequence of SMARCB1 were identified. Five of them were classified as deleterious. All five patients carrying a SMARCB1 mutation had more multiple schwannomas, corresponding to 10.2% of patients with schwannomatosis. They were also diagnosed before 35 years of age. CONCLUSIONS: These results suggest that patients with schwannomas have a significant probability of carrying a SMARCB1 mutation. Combined with data available from other studies, they confirm the clinical indications for genetic screening of the SMARCB1 gene.
Fichier principal
Vignette du fichier
1471-2377-11-9.pdf (96.16 Ko) Télécharger le fichier
1471-2377-11-9.xml (27.88 Ko) Télécharger le fichier
Origin : Publisher files allowed on an open archive
Format : Other
Loading...

Dates and versions

inserm-00668426 , version 1 (09-02-2012)

Identifiers

Cite

Guillaume Rousseau, Tetsuro Noguchi, Violaine Bourdon, Hagay Sobol, Sylviane Olschwang. SMARCB1/INI1 germline mutations contribute to 10% of sporadic schwannomatosis.. BMC Neurology, 2011, 11 (1), pp.9. ⟨10.1186/1471-2377-11-9⟩. ⟨inserm-00668426⟩

Collections

INSERM CNRS
67 View
98 Download

Altmetric

Share

Gmail Facebook X LinkedIn More